Search

Introduction: Atopic diseases have been steadily increasing over the past decades and effective disease-modifying treatment options are urgently needed. These studies introduce a novel synthetic Toll-like receptor 4 (TLR4) agonist, INI-2004, with remarkable efficacy as a therapeutic intranasal treatment for seasonal allergic rhinitis. Methods: Using a murine airway allergic sensitization model, the impact of INI-2004 on allergic responses was assessed. Results: One or two intranasal doses of INI-2004 significantly reduced airway resistance, eosinophil influx, and Th2 cytokine production - providing strong evidence of allergic desensitization. Further investigations revealed that a liposomal formulation of INI-2004 exhibited better safety and efficacy profiles compared to aqueous formulations. Importantly, the liposomal formulation demonstrated a 1000-fold increase in the maximum tolerated intravenous dose in pigs. Pre-clinical GLP toxicology studies in rats and pigs confirmed the safety of liposomal INI-2004, supporting its selection for human clinical trials. Discussion: These findings lay the groundwork for the ongoing clinical evaluation of INI-2004 in allergic rhinitis as a stand-alone therapy for individuals poly-sensitized to multiple seasonal allergens. The study underscores the significance of innovative immunotherapy approaches in reshaping the landscape of allergic rhinitis management. [ABSTRACT FROM AUTHOR]

The article explains a new approach for the synthesis of the bicyclic octosyl nucleoside derivative of the enzomycins, the antifungal natural products that belong to the complex peptidyl nucleoside family of antibiotics. The methodology is shown to be much more flexible and accurate, as compared to the conventional approaches.

A study develops an efficient pathway to a strategically functionalized ezoaminuroic acid derivative of the antifungal ezomycins, starting from readily available (R)-glycidol. A key transformation in the synthesis is the region- and stereoselective conversion of the olefinic functionality of a 5,6-dihydropyran-2-one to the C-2, C-3 trans 1,2-amino alcohol moiety as present in ezoaminuroic acid.

Bulgecinine is a nonproteinogenic amino acid component present in bulgecins A, B and C antibiotic glycopeptides. Combining beta-lactam antibiotics with bulgecins, a unique synergistic antibacterial activity against various gram-negative microorganisms is presented.